Short Interest in Lyell Immunopharma, Inc. (NASDAQ:LYEL) Drops By 16.2%

Lyell Immunopharma, Inc. (NASDAQ:LYEL) saw a significant decline in short interest during the month of February. As of February 28th, there was short interest totalling 8,090,000 shares, a decline of 16.2% from the February 13th total of 9,650,000 shares. Approximately 6.5% of the company’s shares are short sold. Based on an average daily volume of 1,160,000 shares, the days-to-cover ratio is currently 7.0 days.

Lyell Immunopharma Stock Down 5.5 %

Shares of NASDAQ:LYEL traded down $0.03 during trading on Thursday, hitting $0.55. The stock had a trading volume of 436,706 shares, compared to its average volume of 1,042,182. The company has a market capitalization of $162.38 million, a PE ratio of -0.70 and a beta of -0.41. The firm’s fifty day moving average is $0.62 and its 200 day moving average is $0.89. Lyell Immunopharma has a 12 month low of $0.48 and a 12 month high of $3.15.

Lyell Immunopharma (NASDAQ:LYEL) last released its quarterly earnings results on Wednesday, March 12th. The company reported ($0.72) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.52). Lyell Immunopharma had a negative return on equity of 34.64% and a negative net margin of 323,792.09%. The firm had revenue of $0.01 million during the quarter. Equities research analysts expect that Lyell Immunopharma will post -0.78 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a “neutral” rating and issued a $1.00 price target on shares of Lyell Immunopharma in a report on Thursday, March 13th.

Insider Buying and Selling

In related news, CEO Lynn Seely acquired 175,000 shares of the stock in a transaction on Friday, March 14th. The shares were acquired at an average price of $0.61 per share, with a total value of $106,750.00. Following the completion of the transaction, the chief executive officer now owns 712,500 shares in the company, valued at approximately $434,625. The trade was a 32.56 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Richard Klausner bought 158,000 shares of Lyell Immunopharma stock in a transaction dated Friday, March 14th. The stock was acquired at an average price of $0.60 per share, with a total value of $94,800.00. Following the purchase, the director now directly owns 843,365 shares of the company’s stock, valued at approximately $506,019. This represents a 23.05 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have acquired a total of 533,000 shares of company stock valued at $313,550 over the last 90 days. 25.10% of the stock is owned by insiders.

Hedge Funds Weigh In On Lyell Immunopharma

Several institutional investors have recently bought and sold shares of LYEL. Decheng Capital LLC acquired a new stake in Lyell Immunopharma during the fourth quarter worth about $7,622,000. Foresite Capital Management V LLC acquired a new position in Lyell Immunopharma in the 4th quarter valued at about $5,205,000. venBio Partners LLC purchased a new position in Lyell Immunopharma in the fourth quarter worth approximately $4,545,000. Geode Capital Management LLC increased its position in shares of Lyell Immunopharma by 2.9% during the 4th quarter. Geode Capital Management LLC now owns 4,137,264 shares of the company’s stock worth $2,648,000 after purchasing an additional 117,303 shares during the last quarter. Finally, State Street Corp raised its stake in shares of Lyell Immunopharma by 1.9% in the 3rd quarter. State Street Corp now owns 3,889,553 shares of the company’s stock valued at $5,368,000 after acquiring an additional 71,233 shares during the period. 66.05% of the stock is owned by hedge funds and other institutional investors.

Lyell Immunopharma Company Profile

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.